Medicenna Therapeutics Says Enrollment for Phase 1/2 Study for It MDNA11 Drug Complete

MT newswire2026/11/04 15:26

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

11:26 AM EST, 11/04/2026 (MT Newswires) -- Medicenna Therapeutics (MDNA.TO) said Wednesday enrolment is complete for the Phase 1/2 ABILITY-1 study of its immunotherapy candidate MDNA11. MDNA11, designed to activate and expand cancer-fighting immune cells, is being tested in combination with Merck's immunotherapy drug Keytruda (pembrolizuma). A total of 152 patients from Canada, the United States, Australia, Europe and South Korea were enrolled in the study. Updated data from ABILITY-1 will be presented during an oral session at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting on Nov. 7 in Phoenix, Arizona. Medicenna shares were last seen up CA$0.03 to CA$0.445 on the Toronto Stock Exchange. Price: 0.45, Change: +0.03, Percent Change: +7.23

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

华尔街见闻•2026/11/09 10:26